Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cannabinoid receptor CB1 antagonists - ACADIA Pharmaceuticals

Next Previous
Drug Profile

Research programme: cannabinoid receptor CB1 antagonists - ACADIA Pharmaceuticals

Latest Information Update: 04 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders; Drug abuse; Obesity

Most Recent Events

  • 31 Dec 2010 Discontinued - Preclinical for Cognition disorders in USA (PO)
  • 31 Dec 2010 Discontinued - Preclinical for Drug abuse in USA (PO)
  • 31 Dec 2010 Discontinued - Preclinical for Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top